Laser irradiation decreases sclerostin expression in bone and osteogenic cells
Authors:
Open Access
- 5 August 2020
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 34 (9) , 12877-12893
Abstract
Anti‐sclerostin monoclonal antibody romosozumab, a treatment for osteoporosis, reduced vertebral fracture risk and clinical fracture. Laser irradiation triggers various effects, including bio‐stimulation, which can induce beneficial therapeutic effects and biological responses. Originally, we performed in vivo experiments to clarify the mechanism of better bone healing in laser‐ablated bone. Here, we evaluated comprehensive and sequential gene expression in Er:YAG laser‐ablated, bur‐drilled, and nontreated control bones, and found laser irradiation suppressed Sost (coding protein: sclerostin) expression in the bone, possibly via stimulation of mechanotransducers. Surprisingly, bio‐stimulation effect of laser suppressed Sost expression in the primary osteogenic cells. Decreased sclerostin expression after laser irradiation was also validated both in vivo and in vitro. In addition, sequential microarray analysis revealed that the gene expression pattern was clearly different at 24 hours after bone ablation between bur‐drilled and laser‐ablated bones. The Hippo signaling pathway was significantly enriched, whereas inflammation‐related pathways were not affected at 6 hours after the laser ablation, indicating that laser irradiation caused mechanical stimulation. Only bur‐drilled bone showed enriched inflammation‐related gene sets and pathways at 24 hours, not in the laser‐ablated bone. Our study suggests that laser irradiation may become a new treatment modality for osteoporosis, by inhibiting sclerostin expression without inducing inflammation.Keywords
This publication has 54 references indexed in Scilit:
- Romosozumab or Alendronate for Fracture Prevention in Women with OsteoporosisNew England Journal of Medicine, 2017
- Romosozumab Treatment in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2016
- A Review of Osteocyte Function and the Emerging Importance of SclerostinJournal of Bone and Joint Surgery, 2014
- Romosozumab in Postmenopausal Women with OsteopeniaNew England Journal of Medicine, 2014
- Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibodyJournal of Bone and Mineral Research, 2010
- The amazing osteocyteJournal of Bone and Mineral Research, 2010
- Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient miceJournal of Bone and Mineral Research, 2010
- Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone StrengthJournal of Bone and Mineral Research, 2008
- Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP-Stimulated Bone FormationJournal of Bone and Mineral Research, 2007
- Sclerostin is a delayed secreted product of osteocytes that inhibits bone formationThe FASEB Journal, 2005